Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 50

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 50
---
 in the
table below. We have, therefore, assumed for the purposes of the following table, that the Selling Securityholders will sell all of the
shares of common stock owned beneficially that are covered by this prospectus, but will not sell any other shares of common stock that
they presently own. The Selling Securityholders have not held any position or office, or otherwise had a material relationship, with us
or any of our subsidiaries within the past three years other than as a result of the ownership of our common stock or other securities.

| 28 |

| Name of Selling Securityholder |     | Shares of       
 Common Stock    
 Beneficially    
 Owned prior     
 to the Offering |        |     | Maximum Number of      
 Shares of Common Stock 
 to be Sold             
 Pursuant to this       
 Prospectus             |           |    |     | Shares of Common   
 Stock Beneficially 
 Owned after        
 Offering           |        |     | Percentage   
 of Shares    
 Beneficially 
 Owned after  
 Offering(2)  |          |
| Armistice Capital, LLC(1)      |     |                 | [____] |     |                        | 1,550,000 | -3 |     |                    | [____] |     |              | 1[____]% |

| (1) | Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the “Master Fund”), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital. |
| (2) | Percentage is based on [__] shares of common stock outstanding as of August [__], 2025 assuming the resale of all of the shares of common stock covered by this prospectus and giving effect to the 4.99% beneficial ownership blockers in the Warrants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| (3) | Assumes the sale of 1